Oncology Central

ASCO18: Taselisib, combined with Faslodex®, halts growth of advanced breast cancer

0
Results from a Phase lll clinical trial, assessing the effectiveness of a new targeted drug, taselisib, demonstrated promising results against advanced breast cancer when combined with standard hormone therapy fulvestrant (Faslodex®).
To view restricted content, please:
Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.